Fukuda Denshi CoFKDSF 83 ROC (Joel Greenblatt) % is 47.03% as of Mar. 2026, which is 39% above its 10-year median of 33.81. GuruFocus rates FKDSF with a GF Score™ of 83/100 and a GF Value™ of $27.79. The stock has 5 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Fukuda Denshi Co ranks better than 81.79% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Fukuda Denshi Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 47.03%.
The historical rank and industry rank for Fukuda Denshi Co's ROC (Joel Greenblatt) % or its related term are showing as below:
FKDSF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.42 Med: 33.81 Max: 39.63
Current: 33.44
During the past 13 years, Fukuda Denshi Co's highest ROC (Joel Greenblatt) % was 39.63%. The lowest was 26.42%. And the median was 33.81%.
FKDSF's ROC (Joel Greenblatt) % is ranked better than 81.79% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.24
vs FKDSF: 33.44
Fukuda Denshi Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.50% per year.
Fukuda Denshi Co (OTCPK:FKDSF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Fukuda Denshi Co ROC (Joel Greenblatt) % Related Terms
Fukuda Denshi Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Fukuda Denshi Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FKDSF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Fukuda Denshi Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fukuda Denshi Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fukuda Denshi Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Fukuda Denshi Co's ROC (Joel Greenblatt) % falls into.
Fukuda Denshi Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 47.03% mean?
Fukuda Denshi Co (FKDSF) has a ROC (Joel Greenblatt) % of 47.03% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fukuda Denshi Co and its competitors. This is 39% above median its historical median of 33.81. Over the past decade, Fukuda Denshi Co's ROC (Joel Greenblatt) % has ranged from 26.42 to 39.63. According to the industry distribution chart, Fukuda Denshi Co ranks #153 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 18.2%.
Is Fukuda Denshi Co's ROC (Joel Greenblatt) % too high?
Fukuda Denshi Co's current ROC (Joel Greenblatt) % of 47.03% is 39% above median its 10-year median of 33.81. Over the past 10 years, this metric has ranged from a low of 26.42 to a high of 39.63. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.24. Fukuda Denshi Co's value of 47.03% is 1009.2% above this industry median. Based on the distribution chart, Fukuda Denshi Co ranks #153 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fukuda Denshi Co has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Fukuda Denshi Co's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Fukuda Denshi Co ranks #153 out of 840 companies for ROC (Joel Greenblatt) %. This places Fukuda Denshi Co in the top 18% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.24. Fukuda Denshi Co's value of 47.03% is 1009.2% above this benchmark. Historically, Fukuda Denshi Co's own ROC (Joel Greenblatt) % has ranged from 26.42 to 39.63 over the past decade. While the company's 10-year median is 33.81 vs. the industry median of 4.24, Fukuda Denshi Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.24, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fukuda Denshi Co's current ROC (Joel Greenblatt) % of 47.03% is 1009.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fukuda Denshi Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fukuda Denshi Co's current ROC (Joel Greenblatt) % is 47.03%, which is 39% above median its own 10-year median of 33.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fukuda Denshi Co stock overvalued right now?
Fukuda Denshi Co (FKDSF) has a current ROC (Joel Greenblatt) % of 47.03%. The stock's GF Value™ is $27.79, compared to a current price of $42.55 — trading 53.1% above its estimated fair value. The current ROC (Joel Greenblatt) % is 47.03%, which is 39% above median its 10-year median of 33.81 and 1009.2% above the Medical Devices & Instruments industry median of 4.24. Fukuda Denshi Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Fukuda Denshi Co (FKDSF), the current ROC (Joel Greenblatt) % is 47.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fukuda Denshi Co (FKDSF) Overvalued in 2026?
Based on GuruFocus' analysis, Fukuda Denshi Co stock appears to be overvalued.
The current stock price of $42.55 is trading 53.1% above its estimated GF Value™ of $27.79.
Key valuation signals for FKDSF:
ROC (Joel Greenblatt) %: 47.03% (39% above median its 10-year median of 33.81)
GF Value™: $27.79 vs. price of $42.55 (53.1% above fair value)
Industry Position: 1009.2% above the Medical Devices & Instruments median (#153 of 840)
No single metric tells the full story. See the FKDSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fukuda Denshi Co Ltd develops and manufactures medical electronic equipment. The firm operates in four segments: physiological diagnostic equipment, patient monitoring equipment, medical treatment equipment, and consumables and other products. The physiological diagnostic equipment business sells electrocardiographs, vascular screening systems, and blood cell counters. The patient monitoring equipment segment sells patient monitors and transmitters. The medical treatment equipment segment contributes the largest proportion of revenue and sells pacemakers and medical equipment for home treatment. The consumables and other products segment sells disposable electrodes and consumables used for the firm's devices. Fukuda Denshi generates the vast majority of its sales in Japan.
83GF Score
Get the complete analysis for FKDSF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FKDSF has been successfully added to your 
